Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD

BMC Neurology

Table 2 Description of the Confirmed COVID-19 cases

Case #	Age	Sex	Comorbidities	Disease Duration	*Walking Disability score*	*Rituximab injections times*	*Extended Interval Dosing*	*Recent exacerbation*	*Recent corticosteroid use*	*Self-isolation*	*COVID-19 Exposure*	*Treatment method*	*Admission duration*	*Consequence*
1	42	Male	No	13	1	Twice	No	No	No	No	Yes	Hospital admission	< 2 weeks	Death
2	59	Male	No	4	1	> 4 times	No	No	No	No	Yes	Hospital admission (ICU)	< 2 weeks	Death
3	64	Female	No	4	1	Twice	Yes	No	No	No	Yes	Home care	N/A	Cured
4	41	Male	No	12	1	> 4 times	No	No	No	Yes	No	Home care	N/A	Cured
5	46	Female	No	4	2	> 4 times	No	No	No	Yes	No	Hospital admission	< 2 weeks	Cured
6	49	Female	No	8	2	> 4 times	No	No	No	Yes	Yes	Hospital admission (ICU)	< 2 weeks	Cured
7	42	Male	No	15	2	> 4 times	No	No	No	Yes	No	Hospital admission	< 2 weeks	Cured
8	52	Female	No	6	1	Twice	No	No	No	Yes	No	Home care	N/A	Cured
9	48	Female	No	18	5	> 4 times	Yes	No	Yes	Yes	No	Home care	N/A	Cured

ISSN: 1471-2377